🇺🇸 FDA
Pipeline program

PROGRAF 5 mg, gélule, PROGRAF 1 mg, gélule, IMUREL 25 mg, comprimé pelliculé, CYCLOPHOSPHAMIDE, PROGRAF 0,5 mg, gélule

P140938J

Phase 3 small_molecule active

Quick answer

PROGRAF 5 mg, gélule, PROGRAF 1 mg, gélule, IMUREL 25 mg, comprimé pelliculé, CYCLOPHOSPHAMIDE, PROGRAF 0,5 mg, gélule for Antisynthetase syndrome-related interstitial lung disease is a Phase 3 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
Antisynthetase syndrome-related interstitial lung disease
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials